FDA approves New breast cancer drug
IBRANCE is targeted for post-menopausal women with advanced disease IBRANCE® (palbociclib) is the first and only FDA-approved medication in a new class of treatment for postmenopausal women with ER+/HER2- metastatic breast cancer. Pfizer's IBRANCE (palbociclib) inhibits molecules that play a role in the growth of cancer cells. It is intended for postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have not yet received endocrine-based therapy, the FDA said. IBRANCE is taken in combination with letrozole , a commonly used hormone therapy. A combination of IBRANCE with LETROZOLE delayed disease progression 2X longer than letrozole alone. Common side effects of IBRANCE: Low white and red blood cell counts, fatigue, nausea, upper respiratory infection, diarrhea, vomiting, hair loss, inflammation of the lining of the mouth, decreased appetite, nosebleeds, and damage to t
